<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01404078</url>
  </required_header>
  <id_info>
    <org_study_id>TIPS K</org_study_id>
    <secondary_id>CTRI/2010/091/000054</secondary_id>
    <nct_id>NCT01404078</nct_id>
  </id_info>
  <brief_title>Study to Compare 2 Doses of Polycap Versus Single Dose of Polycap With or Without Pottasium</brief_title>
  <acronym>TIPSK</acronym>
  <official_title>A RCT With Factorial Design to Compare Safety and Efficacy of 2 Capsules of the Indian Polycap Versus a Single Capsule Along With or Without Oral Potassium Among Patients With Stable Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. John's Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. John's Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized double blind 2x2 factorial controlled trial to evaluate efficacy
      tolerability of low strength Polycap versus two doses of low strength Polycap in patients
      with stable cardiovascular disease in reducing blood pressure and LDL.

      To evaluate the tolerability and safety of low dose potassium supplementation compared to
      placebo in patients with stable cardiovascular disease.

      Approximately 500 patients are planned to be randomized.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mean change in blood pressure between those taking 2capsules of the polycap versus one
      Difference in Rates of early discontinuation between 2 capsules of polycap versus one Rates
      of reported adverse effects among those taking the polycap
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BLOOD PRESSURE LIPIDS</measure>
    <time_frame>8 weeks</time_frame>
    <description>Amongst patients with cardiovascular disease or type 2 diabetes, the study aims to test the safety and efficacy of giving double dose of polycap versus a single dose of polycap for 8 weeks; efficacy to lower blood pressure and elevated lipids and safety assessed as difference with tolerance to double dose of polycap compared to a single dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability of a Double Dose of Half Strength Polycap</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure Reduction and Lipid Lowering in Type 2 Diabetics</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">518</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Ischemic Stroke</condition>
  <condition>Peripheral Vascular Disease</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>SD Polycap without potassium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose polycap without pottasium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DD Polycap plus potassium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double Dose polycap with potassium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single Dose Polycap</intervention_name>
    <description>Low strength polycap contains Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin</description>
    <arm_group_label>SD Polycap without potassium</arm_group_label>
    <other_name>Polycap</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Double dose Polycap</intervention_name>
    <description>2 Capsules of low strength polycap with 30mEq of Potassium</description>
    <arm_group_label>DD Polycap plus potassium</arm_group_label>
    <other_name>Full dose polycap</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Individuals 40 years and above, with a seated blood pressure &gt; 130/80 mm Hg on two
             consecutive readings (or BP &gt; 120/80 mm Hg in patients under treatment with 2 or more
             antihypertensive medication) with one of the following

               1. Coronary artery disease; previous myocardial infarction (&gt;7 days post
                  uncomplicated MI), or

               2. Ischemic heart disease with significant ECG changes or a positive stress test, or

               3. Stable angina or unstable angina and with documented evidence of multi-vessel
                  (angiography or ECG or CT angiography) coronary artery disease, or

               4. PTCA or CABG Surgery &gt;30 days before informed consent.

               5. Cerebrovascular disease; Previous Ischemic stroke or Transient Ischemic Attacks
                  &gt;30 days before informed consent.

               6. High risk diabetes mellitus defined as HbA1C &gt;7.5%, with microalbuminuria or
                  blood pressure &gt;140/90 mm Hg.

               7. Peripheral artery disease defined as a current or prior history of: physician
                  diagnosed intermittent claudication or vascular surgery for atherosclerotic
                  disease or an ankle/arm systolic blood pressure ratio ≤ 0.90 in either leg at
                  rest, or angiographic or doppler study demonstrating ≥ 70% stenosis in a
                  noncardiac artery.

          2. Those who provide informed consent and can comply with medications and follow-up
             visits.

        Exclusion Criteria:

          1. Known hypersensitivity or intolerance to any of the study medications or a clear
             indication for full doses of beta blockers, RAAS blockers (ACEi, ARBs, Renin
             inhibitors, etc.), diuretics and statins.

          2. History of bleeding or having hemorrhagic stroke anytime in the past or a need for
             continued anticoagulation therapy.

          3. Patients having indication for higher doses of aspirin or needing more than 75mg of
             clopidogrel daily.

          4. Have significant bradycardia (heart rate &lt;50 beats/min) or second- or third-degree
             heart block without a pacemaker.

          5. Planned cardiac surgery or PTCA or any non-cardiac surgery &lt;3months of eligibility
             assessment.

          6. Heart transplant recipient.

          7. Renal dysfunction defined as serum creatinine &gt;2 mg/dL and/or serum potassium &gt;5.0
             mEq/L.

          8. Patients aged &gt;70 years, with mild renal dysfunction defined as serum creatinine &gt;124
             µmol/L (1.4 mg/dL) or eGFR &lt;45 ml/min/1.73 m2.

          9. Hepatic dysfunction, SGOT or SGPT &gt; 3 x ULN.

         10. Taking another experimental drug or within 30days of last dose of the experimental
             drug.

         11. Peptic ulcer disease with bleed, or bleeding diathesis.

         12. Bronchial asthma or Chronic Obstructive Pulmonary Disease with asthma.

         13. Gout, rheumatoid arthritis or other chronic inflammatory disease requiring long-term
             medications with NSAIDs.

         14. Any history of muscular pain, other pathology of the muscles or past history of
             muscular pain secondary to taking statins or fibrates.

         15. Pregnancy or lactating or women of childbearing potential with inadequate
             contraception.

         16. Inability to attend follow up visits (due to significant disability, inadequate
             address or contact details, subject from a far off place, psychiatric illness etc.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr.Prem - Pais, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St.Johns Research Institute</affiliation>
  </overall_official>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/22787067</url>
    <description>Pubmed Abstract</description>
  </link>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2011</study_first_submitted>
  <study_first_submitted_qc>July 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2011</study_first_posted>
  <results_first_submitted>May 19, 2014</results_first_submitted>
  <results_first_submitted_qc>November 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 1, 2014</results_first_posted>
  <last_update_submitted>November 26, 2014</last_update_submitted>
  <last_update_submitted_qc>November 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Hospitals in India identified potential consenting eligible subjects with a history of stable cardiovascular disease or high risk for cardiovascular disease and subjected them to an active run in with single dose and then double dose of polycap. Only patients successfully completing the active run in (&gt;80% compliant) were randomized into the trial</recruitment_details>
      <pre_assignment_details>725 Started on Phase 1 run in low dose polycap 645 started on phase 2 run in full dose polycap Only patients who fulfilled &gt;80% compliance to full dose polycap were randomized to the trial</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>One Dose of Low Srength Polycap</title>
          <description>Patients in this arm will receive one dose of low strength Polycap
Indian Polycap: Polycap contains 5 drugs at half doses Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin</description>
        </group>
        <group group_id="P2">
          <title>Two Doses of Low Strength Polycap</title>
          <description>Patients in this arm will receive 2 doses of low strength Polycap.
Indian Polycap: Polycap contains 5 drugs at half doses Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="261">725 Started on Phase 1 run in low dose polycap 645 started on phase 2 run in full dose polycap</participants>
                <participants group_id="P2" count="257">725 Started on Phase 1 run in low dose polycap 645 started on phase 2 run in full dose polycap</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="243"/>
                <participants group_id="P2" count="237"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Polycap Single Dose</title>
          <description>Patients in this arm received single dose of low strength Polycap only Indian Polycap: Polycap contains 5 drugs at half doses Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin</description>
        </group>
        <group group_id="B2">
          <title>Polycap Double Dose Plus Potassium</title>
          <description>Patients in this arm received one dose of low strength Polycap with potassium
Indian Polycap: Polycap contains 5 drugs at half doses Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="257"/>
            <count group_id="B2" value="261"/>
            <count group_id="B3" value="518"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.2" spread="19.4"/>
                    <measurement group_id="B2" value="57.9" spread="19.2"/>
                    <measurement group_id="B3" value="57.6" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="257"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>BLOOD PRESSURE LIPIDS</title>
        <description>Amongst patients with cardiovascular disease or type 2 diabetes, the study aims to test the safety and efficacy of giving double dose of polycap versus a single dose of polycap for 8 weeks; efficacy to lower blood pressure and elevated lipids and safety assessed as difference with tolerance to double dose of polycap compared to a single dose.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Two Doses of Low Strength Polycap</title>
            <description>Patients in this arm will receive 2 doses of low strength Polycap.
Indian Polycap: Polycap contains 5 drugs at half doses Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin</description>
          </group>
          <group group_id="O2">
            <title>One Dose of Low Srength Polycap</title>
            <description>Patients in this arm will receive one dose of low strength Polycap
Indian Polycap: Polycap contains 5 drugs at half doses Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin</description>
          </group>
        </group_list>
        <measure>
          <title>BLOOD PRESSURE LIPIDS</title>
          <description>Amongst patients with cardiovascular disease or type 2 diabetes, the study aims to test the safety and efficacy of giving double dose of polycap versus a single dose of polycap for 8 weeks; efficacy to lower blood pressure and elevated lipids and safety assessed as difference with tolerance to double dose of polycap compared to a single dose.</description>
          <units>mmHG</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.6" lower_limit="122.4" upper_limit="132.6"/>
                    <measurement group_id="O2" value="129.9" lower_limit="127.5" upper_limit="131.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tolerability of a Double Dose of Half Strength Polycap</title>
        <time_frame>8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure Reduction and Lipid Lowering in Type 2 Diabetics</title>
        <time_frame>8 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Two Doses of Low Strength Polycap</title>
          <description>Patients in this arm will receive 2 doses of low strength Polycap.
Indian Polycap: Polycap contains 5 drugs at half doses Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin</description>
        </group>
        <group group_id="E2">
          <title>One Dose of Low Srength Polycap</title>
          <description>Patients in this arm will receive one dose of low strength Polycap
Indian Polycap: Polycap contains 5 drugs at half doses Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="257"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Alben Sigamani</name_or_title>
      <organization>St John's Research Institute</organization>
      <phone>+918049467080</phone>
      <email>alben@sjri.res.in</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

